NewAmsterdam Pharma Company N.V (NAMS) Revenue & Earnings 2023-2026

Revenue, EBITDA, operating income, net income, EPS, and shares

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares across quarters

TTM Revenue: $22.57M
Q. Revenue: $3.04M
TTM EBITDA: $-214.84M
TTM Op. Income: $-215.18M
Q. Op. Income: $-58.42M
TTM Net Income: $-212.73M
Q. Net Income: $-48.44M
EPS: $-0.4
Shares Out.: $121.72M

$22.57M in TTM revenue declined 52.1% YoY, reaching $3.04M last quarter. TTM EBITDA of $-214.84M and TTM operating income of $-215.18M shows growth is flowing through. However, net income is negative at $212.73M — growth is not yet reaching the bottom line. Revenue is contracting — assess whether this is cyclical or structural.

TTM Revenue

Reveals whether the core business is growing or shrinking

Quarterly Revenue

Highlights seasonal patterns and short-term momentum

TTM EBITDA

Shows if underlying operating profitability is improving

Quarterly EBITDA

Tracks near-term operating profitability trends

TTM Operating Income

Smoothed operating profit over the past four quarters

Quarterly Operating Income

Profit from core operations before financing costs

TTM Net Income

The bottom line — is the company making more money?

Quarterly Net Income

Short-term profit after all expenses and taxes

EPS

Earnings per share — profit attributable to each share

Shares Outstanding

Declining means buybacks benefit remaining holders